{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-043559","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2026-06-16T20:30:16+00:00","discovered_at":"2026-06-16T20:31:00.335891+00:00","generated_at":"2026-06-16T20:35:22.401754+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arvinas, Pfizer, Rigel close VEPPANU license deal; $70M upfront received","bullets":["HSR waiting period terminated June 11, 2026, making License Agreement effective.","Rigel paid $70M aggregate upfront to Arvinas and Pfizer, split evenly.","Additional $15M payable upon successful completion of transition activities.","Up to $320M in development, regulatory, and commercial milestones plus tiered royalties.","Milestones and royalties replace unearned payments from Pfizer to Arvinas under prior collaboration."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-043559","json":"https://secwatch.observer/filing/0001628280-26-043559.json","markdown":"https://secwatch.observer/filing/0001628280-26-043559.md","text":"https://secwatch.observer/filing/0001628280-26-043559.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000162828026043559/0001628280-26-043559-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000162828026043559/arvn-20260611.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T20:35:22.401754+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}